Roberto Buonaiuto, Breast Medical Oncology Resident at the National Cancer Institute IRCCS Fondazione G. Pascale and Research Fellow at the Jules Bordet Institute, shared a post on X:
“Just out in JNCI.
Do Trop-2 ADCs work differently by Trop-2 expression? Our meta-analysis found greater PFS benefit in Trop-2-high tumors. A timely question as treatment choices shift from chemo vs ADC to ADC vs ADC.”
Title: Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis
Authors: Roberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, Maria Letizia Cataldo, Luca Arecco, Riccardo Gerosa, Gabriella Gentile, Aldo Caltavituro, Ines Barone, Bengisu Karakose, Elisa Agostinetto, Christos Sotiriou, Michelino De Laurentiis, Evandro De Azambuja, Carmine De Angelis
Read the full article.
Other articles about ADCs on OncoDaily.